BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ConfometRx Announces Patent on International GPCR Structural Analysis


10/12/2012 9:35:23 AM

SANTA CLARA, Calif., Oct. 11, 2012 /PRNewswire-USNewswire/ -- ConfometRx is pleased to announce that the U.S. Patent and Trademark Office (USPTO) recently awarded Stanford University another important patent covering methods of analyzing G protein coupled receptor (GPCR) crystal structures and selecting GPCR modulators using the proprietary T4-lysozyme (T4-L) fusion technology. This new patent is also exclusively licensed to ConfometRx. Importantly, this patent prevents the use of the proprietary T4-lysozyme (T4-L) fusion technology overseas where any resulting GPCR modulators are imported or used in the United States.

(Logo: http://photos.prnewswire.com/prnh/20120228/DC61335LOGO)

ConfometRx, a leader in G protein coupled receptor (GPCR) structural characterization and analysis, has exclusive rights to the patented T4-lysozyme (T4-L) protein fusion stabilization technology used to solve at least thirteen novel GPCR structures. This pioneering protein fusion technology was developed by Stanford Professor and ConfometRx co-Founder, Dr. Brian Kobilka, and Stanford University has been awarded six separate patents on this fundamental technology with other patents still pending both in the United States and abroad.

The T4-L method has been validated and successfully applied to solve at least thirteen novel GPCR structures, including the beta 2 adrenergic receptor, the D3 dopamine receptor, the CXCR4 receptor, the H1 histamine receptor, the S1P1 receptor, the A2A adenosine receptor, the mu, delta, and kappa-opioid receptors, the M2 and M3 muscarinic receptors which have been reported in Science and Nature. In addition to these published structures, T4-L technology has recently been used to crystallize the M1 muscarinic receptor in ConfometRx, as well as the protease activated receptor PAR1 (also known as the thrombin receptor) in the Kobilka lab.

If you have any questions or would like to learn more about ConfometRx's proprietary technology or to discuss a possible partnering arrangement in the United States or abroad, please contact Dickstein Shapiro LLP, Attn: Deborah Fishman, 700 Hansen Way, Palo Alto, CA 94304, phone: (650) 690-9500, fax: (650) 690-9501, e-mail: fishmand@dicksteinshapiro.com.

SOURCE ConfometRx



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES